Sodium Pyruvate Surfactant Composition for Lung Function
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic hypoxemia and pulmonary dysfunction, caused by decreased lung surfactant synthesis, fail to effectively enhance oxygen saturation and reduce lung tightness and coughing, particularly in patients with lung diseases and injuries.
Innovation Solution
A sodium pyruvate solution with calcium, phosphate, and magnesium is inhaled to enhance the synthesis of lung surfactants, increasing oxygen saturation and reducing lung tightness and coughing, while also improving drug uptake and efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for chronic hypoxemia and pulmonary dysfunction, then basic symptom management is provided, but oxygen saturation remains low and lung tightness and coughing are not effectively reduced
Solution Approach 1:
The patent combines multiple nutrients (sodium pyruvate, calcium, phosphate, magnesium) into a single synergistic composition that works together to enhance lung surfactant synthesis. This merging of multiple components addresses the limitation of conventional single-ingredient treatments while achieving reliable therapeutic effects for chronic hypoxemia and pulmonary dysfunction
Solution Approach 2:
The invention uses a composite nutritional composition where sodium pyruvate, calcium, phosphate, and magnesium work synergistically to produce therapeutic effects greater than the sum of individual components. This composite approach resolves the contradiction by providing effective treatment through a multi-component formulation rather than simple monotherapies
2Productivity
If lung surfactant synthesis is enhanced through nutritional supplementation, then oxygen saturation and lung function improve, but the treatment requires multiple nutrients working synergistically
Solution Approach 1:
The patent merges sodium pyruvate, calcium, phosphate, and magnesium into a unified composition that synergistically enhances lung surfactant production. This combination approach achieves high productivity in surfactant synthesis while managing composition complexity through integrated formulation rather than separate administrations
Solution Approach 2:
The nutritional composition serves multiple functions simultaneously: sodium pyruvate provides energy for synthesis, calcium and magnesium act as cofactors for enzymatic reactions, and phosphate contributes to phospholipid structure. This multi-functionality within a single composition enables high surfactant production without requiring multiple separate treatment interventions
3Ease of operation
If the synergistic composition is administered, then lung tightness and coughing are reduced and drug uptake improves, but the treatment requires specific concentrations of multiple minerals
Solution Approach 1:
The patent specifies precise concentration ranges for each nutrient component (sodium pyruvate 0.1-10 mM, calcium 0.01-5 mM, phosphate 0.01-5 mM, magnesium 0.01-5 mM) to optimize therapeutic effects. This parameter control enables effective symptom relief while providing clear manufacturing guidelines to manage concentration precision requirements
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination of sodium pyruvate with calcium, phosphate, and magnesium significantly increases lung surfactant production, enhancing oxygen saturation, reducing lung tightness and coughing, and improving lung function in patients with chronic hypoxemia, including those with COPD and asthma.
Implementation Method 1
The present invention is based on the discovery that the pulmonary dysfunction, characteristic of certain disease states, is attributable to the decrease in the synthesis of surfactants and other secretory molecules normally produced by type II alveolar cells, leading to lung tightness, reduced lung capacity and volume, coughing, dyspnea and Hypoxemia
Data Source
AI summary
Methods for the treatment of patients with both Chronic Obstructive Pulmonary Disease (COPD) and pulmonary fibrosis, and of patients with idiopathic pulmonary fibrosis without COPD, by stimulating the synthesis of human and animal patient lung and sinus surfactants to increase lung functions, inhibiting fibrosis and reducing coughing and nasal erythema, include the following steps: A) analyzing and diagnosing a patient with a lung ailment selected from the group consisting of i) both COPD and pulmonary fibrosis; and ii) idiopathic pulmonary fibrosis without COPD; and, B) treating the patient to raise the patient's lung functions including FEV1/FVC ratio by contacting mammalian cells with a [therapeutically effective amount of a treatment] composition that includes: a) a pyruvate salt; b) a phosphate; c) a salt of calcium; and d) a salt of magnesium, in an aqueous carrier, containing no more than 2.2 grams of said pyruvate salt per liter.